July 12, 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome. The study involves testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing technology so clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.
“MyeloMATCH is an immense step forward for patients with aggressive and rapidly advancing cancers who need better treatment options,” John Sos, SVP and president of life sciences solutions at Thermo Fisher Scientific, said in a press statement. “Using the Genexus System, clinical teams across sites can quickly match eligible patients with the right trials to ultimately better understand the clinical impact of these therapies. By helping to expedite this process, we can ensure that more patients have access to appropriate precision oncology treatments.”
The study aims to deliver results within a few days across testing modalities to help quickly enroll patients into specific substudies based on their biomarker profile at time of diagnosis. Thermo Fisher’s Ion Torrent Genexus system automates the specimen-to-report workflow and is designed to deliver results in one day.